[Effects of colloidal bismuth subcitrate and aluminum hydroxide on gastric and duodenal levels of prostaglandin E2].
D000328:Adult; D000536:Aluminum Hydroxide / Q000494:pharmacology* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001729:Bismuth / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015232:Dinoprostone; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy; D004386:Duodenum / Q000032:analysis*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000032:analysis*; D006801:Humans; D007413:Intestinal Mucosa / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D011458:Prostaglandins E / Q000032:analysis*
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D011458:Prostaglandins E; D000536:Aluminum Hydroxide; C002791:bismuth tripotassium dicitrate; D015232:Dinoprostone; D001729:Bismuth
Efectos del subcitrato de bismuto coloidal e hidróxido de aluminio sobre los niveles gástricos y duodenales de prostaglandina E2.